A phase II observer-blind, randomized, controlled, multi-center trial to evaluate the safety and immunogenicity of different formulations of monovalent Influenza A/mallard/Netherlands/12/2000 NIBRG-63 (H7N1) vaccine manufactured in Quebec, Canada with AS03 adjuvant, given as a two-dose series to adults 65 years of age and older.